Metformin does not directly damage healthy kidneys or a healthy liver. The real concern is what happens when one of those organs is already struggling: metformin is cleared almost entirely through the kidneys, so impaired kidney function causes the drug to accumulate, raising the risk of a rare but serious complication called lactic acidosis. On the liver side, direct drug-induced liver injury from metformin is documented only in isolated case reports and is considered extremely uncommon. The relationship between metformin and these two organs is more nuanced than a simple yes-or-no, though, because emerging evidence suggests the drug may actually protect both organs under certain conditions.
Why Kidney Function Is the Key Safety Variable
Metformin itself is not toxic to kidney tissue. Your kidneys do not break it down; they simply filter it out of the blood and excrete it in urine, largely unchanged. When kidneys work normally, this process keeps metformin at safe levels. When kidney function drops, the drug stays in the bloodstream longer and reaches higher concentrations. That buildup can shift your body’s metabolism toward producing more lactic acid while simultaneously reducing your ability to clear it. The result, in severe cases, is metformin-associated lactic acidosis, or MALA, a condition where blood becomes dangerously acidic.1PubMed Central. Metformin-associated lactic acidosis: A mini review of pathophysiology, diagnosis and management in critically ill patients
MALA is rare in absolute terms. Most people who take metformin for years never experience it. But when it does happen, it tends to happen in people whose kidney function has deteriorated, sometimes without their knowledge. This is why routine kidney monitoring is standard for anyone on the drug. The risk is not that metformin attacks the kidneys; it is that failing kidneys cannot do their job of keeping metformin levels in check.
The eGFR Thresholds That Guide Prescribing
Doctors use a measure called eGFR (estimated glomerular filtration rate) to gauge how well your kidneys are filtering. Guidelines from multiple diabetes and nephrology organizations have converged on a tiered system for metformin use based on this number:
- eGFR 45 or above: Metformin can be used safely at standard doses.
- eGFR 30 to 44: Metformin should not be newly started. If you are already taking it, the daily dose should be capped at 1,000 mg or lower, with more frequent kidney monitoring.
- eGFR below 30: Metformin is contraindicated and should be stopped.
These thresholds come from a consensus between the Korean Diabetes Association and the Korean Society of Nephrology, but they align closely with guidance from the U.S. FDA and European regulators.2PubMed Central. Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement Historically, guidelines varied widely across countries. A review of international recommendations found that some nations used qualitative language (“use with caution in renal impairment”) while others set specific cutoffs, and the quantitative thresholds ranged from an eGFR of 60 all the way down to advanced kidney failure.3PubMed. Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world The trend over the past decade has been toward loosening restrictions, allowing metformin use further into moderate kidney disease than older guidelines permitted.
Does Stopping Metformin Actually Help in Advanced Kidney Disease?
One question that has vexed researchers is whether pulling the plug on metformin when kidney function drops into stage 4 territory (eGFR 15 to 29) truly improves outcomes or just removes a beneficial drug at the worst time. A nationwide Scottish study emulating a clinical trial found that patients who continued metformin for at least six months after reaching stage 4 kidney disease had higher three-year survival than those who stopped it promptly: about 70% versus 63%. After accounting for other health differences between the groups, stopping metformin was linked to a 23% higher risk of dying.4American Journal of Kidney Diseases. Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study
This does not mean everyone with severely reduced kidney function should keep taking metformin. The study also noted that continuing it did not reduce the rate of major cardiovascular events. And some observational data point in the other direction: one analysis of patients with moderate chronic kidney disease found that continuing metformin was associated with a steeper decline in kidney filtration rate compared to stopping it.5Europe PMC / Oncotarget. Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease The takeaway is that the decision to continue or stop metformin in advanced kidney disease is genuinely case-by-case and depends on the individual’s full medical picture, not just one lab value.
Evidence That Metformin May Protect the Kidneys
Somewhat counterintuitively, a body of experimental research suggests metformin has kidney-protective properties. Laboratory and animal studies show that the drug activates a cellular energy sensor called AMPK, along with several independent pathways, in ways that reduce inflammation, oxidative stress, and fibrosis in kidney tissue.6PubMed Central. Metformin: the updated protective property in kidney disease In plain terms, metformin appears to dial down some of the biological processes that cause kidneys to scar and lose function over time.
Whether these protective effects translate into meaningful clinical benefit in humans is still an open question. Most of the evidence comes from animal models and cell-culture experiments, which do not always predict what happens in people. But the research helps explain why observational studies sometimes find that metformin users have slower kidney decline than people on other diabetes medications. The paradox is real: a drug that requires healthy kidneys to be used safely may also help keep kidneys healthy.
Direct Liver Damage From Metformin Is Extremely Rare
The liver story is simpler than the kidney story, at least when it comes to direct harm. Metformin-induced hepatotoxicity, meaning liver injury caused by the drug itself, is documented primarily in scattered case reports and is considered an extremely rare, idiosyncratic reaction.7Europe PMC / American Diabetes Association. Metformin-induced hepatotoxicity “Idiosyncratic” here means it is not dose-dependent or predictable; it happens in a handful of individuals for reasons that are not fully understood, likely related to their particular biology.
For context, metformin is one of the most widely prescribed drugs on Earth, with hundreds of millions of prescriptions filled each year. If it carried a meaningful risk of liver damage, signal would have emerged long ago in pharmacovigilance databases. The older diabetes drug phenformin, a chemical relative of metformin, was pulled from most markets decades ago partly because of its toxicity profile, but metformin has a much cleaner safety record. Routine liver function testing is not required specifically because of metformin, though your doctor may check liver enzymes as part of general diabetes management.
Metformin and Fatty Liver Disease
Many people with type 2 diabetes also have non-alcoholic fatty liver disease (now often called metabolic dysfunction-associated steatotic liver disease). Because metformin improves insulin sensitivity and lowers blood sugar, there has been longstanding hope that it might also help clear fat from the liver and reduce liver inflammation. The reality is more modest.
A meta-analysis of randomized controlled trials in children and adolescents with fatty liver disease found that metformin failed to produce a statistically significant improvement in liver enzyme levels, which are the standard blood marker for liver inflammation.8PubMed Central. The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials Adult studies have been similarly underwhelming. Current guidelines generally do not recommend metformin specifically for treating fatty liver disease, even though it remains a perfectly reasonable diabetes drug for patients who happen to have the condition. If your doctor prescribes metformin and you also have fatty liver, the drug is unlikely to make the liver problem worse, but it probably will not fix it either.
The Complicated Picture in Cirrhosis
Cirrhosis, where extensive scarring has replaced healthy liver tissue, is where the metformin-liver conversation gets genuinely complicated. The liver plays a role in lactate metabolism, so severe liver disease independently raises the risk of lactic acidosis, making the combination with metformin theoretically more dangerous.
Yet multiple studies have found that diabetic patients who continued metformin after a cirrhosis diagnosis lived significantly longer than those who stopped. One study reported median survival of nearly 12 years in patients who continued the drug versus about 5.6 years in those who discontinued, and no cases of MALA occurred in the metformin group during follow-up. After adjustment, continuing metformin reduced the risk of death by 57%.9PubMed Central. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes Other research has linked metformin use in compensated cirrhosis to lower rates of liver cancer and hepatic decompensation, the dangerous worsening of liver function that leads to complications like fluid buildup and confusion.10Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential
Not all evidence agrees. A large population-based study from Taiwan found that metformin use was associated with a 13% higher risk of mortality and a 15% higher risk of cirrhotic decompensation compared to non-use, with the risk climbing at daily doses above 1,000 mg.11PubMed Central. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis The dose-dependent pattern in that study is notable: lower doses appeared safer, suggesting that cirrhotic patients who do use metformin may benefit from keeping the dose modest.
The emerging consensus, to the extent one exists, is that metformin can be used in compensated cirrhosis (where the liver still functions reasonably well) with caution and dose restraint. It should be avoided or used very carefully when liver impairment is moderate to severe, and it is generally contraindicated when cirrhosis is accompanied by significant kidney impairment, because the combined risk of lactic acidosis from both failing organs becomes too high.
Drug Interactions That Raise the Stakes
Metformin enters and exits cells through specialized transporter proteins in the kidneys, gut, and liver. Other medications that use or block these same transporters can effectively raise metformin concentrations in the blood, even if your kidney function is normal. A review of metformin drug interactions found that most problematic interactions involve drugs that inhibit a family of transporters called OCTs and MATEs, leading to higher circulating metformin levels and a greater risk of lactic acidosis.12PubMed Central. Drug Interactions of Metformin Involving Drug Transporter Proteins
Common culprits include certain blood pressure medications, antifungal drugs, and some antibiotics. The practical implication is that you should make sure every prescriber you see knows you take metformin. The interaction risk is manageable when it is recognized, but it becomes dangerous when a new medication quietly drives metformin levels up in someone whose kidneys are already borderline.
Acute Illness, Contrast Dye, and Temporary Holds
Even if you have been taking metformin safely for years, there are situations where your doctor may tell you to pause it temporarily. The classic scenario involves iodinated contrast dye, the fluid injected for CT scans and certain cardiac procedures. Contrast dye can temporarily reduce kidney function, which could cause metformin to accumulate. The standard practice is to hold metformin before the procedure in patients whose kidney function is already reduced (eGFR below 60) or in those with other risk factors, and restart it once kidney function has been confirmed as stable afterward.13Journal of Renal Injury Prevention. Continuation or termination of metformin in diabetic patients exposed to iodinated contrast medium? For people with normal kidney function and no complicating conditions, some guidelines no longer require stopping metformin at all.
Acute illness that causes dehydration, sepsis, or sudden drops in blood pressure follows a similar logic. Any condition that acutely impairs kidney perfusion can trigger the same accumulation problem. If you are hospitalized or seriously ill with vomiting and diarrhea, your medical team will likely hold metformin until things stabilize. This is not because the drug is damaging your organs in that moment; it is because your organs temporarily cannot handle it.
What Happens When MALA Does Occur
When metformin-associated lactic acidosis develops, it is a medical emergency that typically unfolds in an intensive care setting. Symptoms come on as nausea, rapid breathing, abdominal pain, and confusion, progressing to cardiovascular collapse in severe cases. Treatment involves supportive care, correcting the acidosis with bicarbonate infusions, and often hemodialysis to physically remove metformin from the blood.14PubMed Central. Should dialysis be offered in all cases of metformin-associated lactic acidosis? In one ICU evaluation, the mortality rate was similar between patients who received dialysis and those who did not, but the dialyzed patients had been sicker to begin with, suggesting dialysis was pulling its weight in the most critical cases.
Severe MALA can sometimes resist standard dialysis, requiring additional interventions or prolonged renal replacement therapy.15PubMed Central. Treatment of severe metformin-associated lactic acidosis with renal replacement therapy and tris-hydroxymethyl aminomethane: a case report The good news is that patients who survive the acute episode generally recover without lasting organ damage from the metformin itself. The bad news is that MALA tends to occur in people who already had significant underlying disease, making the overall prognosis worse.
Practical Monitoring If You Take Metformin
For most people with type 2 diabetes and normal organ function, metformin remains one of the safest and most effective first-line treatments available. It has decades of real-world use behind it. The monitoring that keeps it safe is straightforward:
- Kidney function checks: At least once a year for people with normal eGFR, and more frequently (every three to six months) if eGFR is in the 30 to 60 range.
- Awareness of acute triggers: Dehydration, severe illness, contrast dye procedures, and new medications can all temporarily change the risk equation. Knowing when to pause metformin matters more than worrying about its long-term effects.
- Dose adjustment: If kidney function declines over time, your dose may need to come down before the drug needs to be stopped entirely. The stepped approach is more common now than the binary on-or-off decisions of older guidelines.
- Liver considerations: Routine liver enzyme testing solely because of metformin is not typically required. If you have known liver disease, especially cirrhosis, your doctor will weigh the benefits of metformin against the severity of your liver impairment.
The fear that metformin is silently destroying your kidneys or liver while you take it for diabetes is not supported by the evidence. The drug does not attack these organs. What it does require is that they function well enough to process it safely, and that you and your doctor keep track of how well they are doing that job over time.
Why the Old Warnings Were So Strict
If metformin is this safe, you might wonder why it carried such alarming warnings for so long. Part of the answer is phenformin. That older biguanide drug, chemically similar to metformin, was withdrawn in most countries in the 1970s because it caused lactic acidosis at an unacceptable rate. Metformin inherited much of phenformin’s stigma by association, and early prescribing guidelines were written with an abundance of caution that arguably kept the drug from patients who would have benefited. The FDA did not approve metformin in the United States until 1995, decades after it was available in Europe, partly because of lingering wariness from the phenformin era.
Over time, large observational studies and expanded clinical experience showed that metformin’s lactic acidosis risk was far lower than phenformin’s. Regulatory agencies gradually relaxed the kidney-function cutoffs, allowing millions more patients access to the drug. The trend continues: as the Scottish target trial emulation study and others suggest, even patients with fairly advanced kidney disease may do better continuing metformin than stopping it, provided they are monitored carefully.4American Journal of Kidney Diseases. Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study The science has moved faster than public perception, and many patients still carry an outdated fear that metformin is hard on their organs when the opposite is closer to the truth for most people.